Archive for the ‘Artificial Intelligence – General’ Category

Digital Therapeutics: A threat or opportunity to pharmaceuticals

Reporter and Curator: Dr. Sudipta Saha, Ph.D.


Digital Therapeutics (DTx) have been defined by the Digital Therapeutics Alliance (DTA) as “delivering evidence based therapeutic interventions to patients, that are driven by software to prevent, manage or treat a medical disorder or disease”. They might come in the form of a smart phone or computer tablet app, or some form of a cloud-based service connected to a wearable device. DTx tend to fall into three groups. Firstly, developers and mental health researchers have built digital solutions which typically provide a form of software delivered Cognitive-Behaviour Therapies (CBT) that help patients change behaviours and develop coping strategies around their condition. Secondly there are the group of Digital Therapeutics which target lifestyle issues, such as diet, exercise and stress, that are associated with chronic conditions, and work by offering personalized support for goal setting and target achievement. Lastly, DTx can be designed to work in combination with existing medication or treatments, helping patients manage their therapies and focus on ensuring the therapy delivers the best outcomes possible.


Pharmaceutical companies are clearly trying to understand what DTx will mean for them. They want to analyze whether it will be a threat or opportunity to their business. For a long time, they have been providing additional support services to patients who take relatively expensive drugs for chronic conditions. A nurse-led service might provide visits and telephone support to diabetics for example who self-inject insulin therapies. But DTx will help broaden the scope of support services because they can be delivered cost-effectively, and importantly have the ability to capture real-world evidence on patient outcomes. They will no-longer be reserved for the most expensive drugs or therapies but could apply to a whole range of common treatments to boost their efficacy. Faced with the arrival of Digital Therapeutics either replacing drugs, or playing an important role alongside therapies, pharmaceutical firms have three options. They can either ignore DTx and focus on developing drug therapies as they have done; they can partner with a growing number of DTx companies to develop software and services complimenting their drugs; or they can start to build their own Digital Therapeutics to work with their products.


Digital Therapeutics will have knock-on effects in health industries, which may be as great as the introduction of therapeutic apps and services themselves. Together with connected health monitoring devices, DTx will offer a near constant stream of data about an individuals’ behavior, real world context around factors affecting their treatment in their everyday lives and emotional and physiological data such as blood pressure and blood sugar levels. Analysis of the resulting data will help create support services tailored to each patient. But who stores and analyses this data is an important question. Strong data governance will be paramount to maintaining trust, and the highly regulated pharmaceutical industry may not be best-placed to handle individual patient data. Meanwhile, the health sector (payers and healthcare providers) is becoming more focused on patient outcomes, and payment for value not volume. The future will say whether pharmaceutical firms enhance the effectiveness of drugs with DTx, or in some cases replace drugs with DTx.


Digital Therapeutics have the potential to change what the pharmaceutical industry sells: rather than a drug it will sell a package of drugs and digital services. But they will also alter who the industry sells to. Pharmaceutical firms have traditionally marketed drugs to doctors, pharmacists and other health professionals, based on the efficacy of a specific product. Soon it could be paid on the outcome of a bundle of digital therapies, medicines and services with a closer connection to both providers and patients. Apart from a notable few, most pharmaceutical firms have taken a cautious approach towards Digital Therapeutics. Now, it is to be observed that how the pharmaceutical companies use DTx to their benefit as well as for the benefit of the general population.





Read Full Post »

VIDEOS: Artificial Intelligence Applications for Cardiology


Reporter: Aviva Lev-Ari, PhD, RN


March 11, 2019 /



VIDEO: Artificial Intelligence Applications for Cardiology


Anthony Chang, M.D., chief intelligence and innovation officer, Children’s Hospital of Orange County (CHOC), and medical director of the Sharon Disney Lund Medical Intelligence and Innovation Institute. He is expert in artificial intelligence (AI). He spoke in several sessions at Healthcare Information and Management Systems Society (HIMSS) 2019 meeting on the integration of AI in healthcare.






Applications for Artificial Intelligence in Cardiovascular Imaging


VIDEO: How Artificial Intelligence Can Detect Brain Bleeds


VIDEO: Artificial Intelligence in Cardiac Imaging


Artificial Intelligence Detects AFib Using Apple Watch Heart Rate Sensor


VIDEO: Example of How Artificial Intelligence Can Improve Patient Care


VIDEO: Use of Artificial Intelligence To Speed Cardiac Clinical Research


Use of Artificial Intelligence to Locate Standard Echo Heart Views


VIDEO: Artificial Intelligence in Cardiac Ultrasound


VIDEO: Examples of Artificial Intelligence in Medical Imaging Diagnostics


VIDEO: Ultrasound’s Integration of Artificial Intelligence and Robotic Echo





From: Diagnostic and Interventional Cardiology <>

Reply-To: <>

Date: Monday, March 11, 2019 at 10:06 AM

To: Aviva Lev-Ari <>

Subject: VIDEO: Artificial intelligence applications for cardiology

Read Full Post »



APRIL 25-27, 2019

315 Trumbull St, Hartford, CT 06103
Reporter: Stephen J. Williams, Ph.D.


The three-day symposium aims to bring oncologists and statisticians together to share new research, discuss novel ideas, ask questions and provide solutions for cancer clinical trials. In the era of big data, precision medicine, and genomics and immune-based oncology, it is crucial to provide a platform for interdisciplinary dialogues among clinical and quantitative scientists. The Stat4Onc Annual Symposium serves as a venue for oncologists and statisticians to communicate their views on trial design and conduct, drug development, and translations to patient care. To be discussed includes big data and genomics for oncology clinical trials, novel dose-finding designs, drug combinations, immune oncology clinical trials, and umbrella/basket oncology trials. An important aspect of Stat4Onc is the participation of researchers across academia, industry, and regulatory agency.

Meeting Agenda will be announced coming soon. For Updated Agenda and Program Speakers please CLICK HERE

The registration of the symposium is via NESS Society PayPal. Click here to register.

Other  2019 Conference Announcement Posts on this Open Access Journal Include:

Read Full Post »

  • World Medical Innovation Forum, Partners Innovations, ARTIFICIAL INTELLIGENCE | APRIL 8–10, 2019 | Westin, BOSTON

Aviva Lev-Ari, PhD, RN Founder, LPBI Group

will cover this event in Real Time





Monday, April 8, 2019

7:00 am – 8:00 am
7:00 am – 5:00 pm
8:00 am – 9:40 am
Bayer Ballroom

First Look

Nine rapid fire presentations on the applications of AI in Clinical Care

Moderator: Giles Boland, MD
  • Chair, Department of Radiology, BWH; Philip H. Cook Professor of Radiology, HMS
Moderator: Trung Do
  • VP, Business Development, Innovation, PHS
9:40 am – 9:55 am
9:55 am – 11:35 am
Bayer Ballroom

First Look

Nine rapid fire presentations on the applications of AI in Clinical Care

11:45 am – 1:00 pm

Discovery Café Sessions

Lunch with Top Leading Experts: Intensive sessions addressing cutting-edge artificial intelligence topics.

Applying AI to Save Lives During the Opioid Crisis

The U.S. is in the throes of a devastating epidemic of opioid addiction and overdose — some 130 people die in this country every day from opioids, says the National Institute on Drug Abuse. With a total economic cost of more than $78 billion a year, academic and industry organizations are harnessing AI to develop new tools that can help alleviate this national crisis. This session will discuss some of the AI-based strategies that academic and industry teams are leveraging to help clinical and public health officials better predict, identify, and treat opioid addiction, as well as some of the concerns around data privacy.

Moderator: Thomas Sequist, MD, Chief Quality & Safety Officer, PHS

Bob Burgin, CEO, Amplifire Healthcare Alliance

Carm Huntress, CEO, RxRevu Inc

Sarah Wakeman, MD, Medical Director, Substance Use Disorder Initiative, MGH; Assistant Professor, Medicine, HMS

Scott Weiner, MD, Director, Brigham Comprehensive Opioid Response and Education (B-CORE) Program, BWH; Assistant Professor, HMS


Community Hospitals: Key Component in Healthcare Transformation

Community hospitals are the largest sources of patient care in the U.S. As such, they represent a critical frontier in the transformation of health care. How are these organizations using AI and digital technologies to drive transformation? What are the key distinctions from academic medical centers? This session will address these and other critical topics that impact community hospitals and their essential, though often overlooked, role in health care.

Moderator: Michael Jaff, DO, President, NWH, PHS, Professor of Medicine, HMS

Fabien Beckers, PhD, CEO, Arterys

Joanna Geisinger, CEO, TORq Interface

Lee Schwamm, MD, Director, Center for TeleHealth and Exec Vice Chair, Neurology, MGH; Professor, Neurology, HMS

Tal Wenderow, CEO, Beyond Verbal


Digital Management of Diabetes

Across the full spectrum of patient care, the management of diabetes has been flooded with new technology and treatment options for both type 1 and type 2 diabetes – there is a range of new devices and software, including automatic insulin infusion systems, glucose sensors, AI-based algorithms and decision support tools, with artificial pancreas on the horizon. This session will focus on these areas as well as clinical use cases that highlight the value of AI.

Moderator: Deborah Wexler, MD, Clinical Director, Diabetes Center, MGH; Associate Professor, HMS

Marie McDonnell, MD, Section Chief and Director, Diabetes Program, BWH; Lecturer, HMS

Joshua Riff, MD, CEO, Onduo


Emergency Medicine


Mental Health and the Promise of AI

Moderator: Sabine Wilhelm, PhD, Chief of Psychology; Director, OCD and Related Disorders Program, MGH; Professor, Psychology, HMS

Thomas McCoy, MD, Director of Research, Center for Quantitative Health, MGH; Assistant Professor, Psychiatry & Medicine, HMS

Christopher Molaro, CEO, Neuroflow

David Silbersweig, MD, Chairman, Department of Psychiatry, BWH; Stanley Cobb Professor of Psychiatry, HMS


From Startup to Impact (Pharma and Diagnostics)

With all the hype surrounding AI, this session will focus on what really matters. Impact! Who is really moving the needle in life sciences today? This session will introduce you to five leading companies who will share their client stories over lunch.

Moderator: James Brink, MD, Radiologist-in-Chief, MGH; Juan M. Taveras Professor of Radiology, HMS

1:00 pm – 1:15 pm
1:15 pm – 1:45 pm
Bayer Ballroom
1:45 pm – 2:35 pm
Bayer Ballroom

AMC AI Strategy: AI from the Top

  • Board Member, PHS; President Emerita and Professor of Neuroscience, MIT
  • Chief Data Science Officer, PHS; Vice Chairman, Radiology, MGH; Associate Professor, Radiology, HMS
  • Chief Academic Officer, PHS; Laurie Carrol Guthart Professor of Medicine, Academic Dean for Partners, HMS; 2019 Forum Co-Chair
  • Chief Clinical Officer, PHS; Professor of Medicine, HMS; 2019 Forum Co-Chair
2:35 pm – 3:25 pm
Bayer Ballroom

RWE and Trial Optimization in the AI Era

Moderator: Thomas Lynch, MD
  • EVP and CSO, R&D, Bristol-Myers Squibb
  • CMO, CSO, SVP Oncology, Flatiron Health
  • EVP MA&PV and Bayer CMO, Bayer AG
  • Chief Architect, Microsoft Healthcare
  • CEO, My Own Med Inc.
  • Executive Director, Clinical Trials Office, PHS; Associate Professor of Medicine, HMS
3:25 pm – 4:15 pm
Bayer Ballroom

AI Driven Value-Based Care

Moderator: Timothy Ferris, MD
  • CEO, MGPO; Professor of Medicine, HMS
  • CEO, American Heart Association
  • EVP, President, Network Solutions Change Healthcare
  • Vice Chairman, Investment Banking and Managing Director Lazard Freres
  • CEO, NHS England
4:15 pm – 5:05 pm
Bayer Ballroom

Cardiovascular Care: Reinvented Through AI

  • Vice Chair for Scientific Innovation, Department of Medicine, BWH; Associate Professor of Medicine, HMS
  • President, Bayer Pharma Americas Region, Bayer
  • Director, Cardiac Imaging MR PET CT Program, MGH; Professor, Medicine, HMS
5:15 pm – 6:15 pm

Tuesday, April 9, 2019

7:00 am – 8:00 am
7:00 am – 5:00 pm
7:50 am – 8:00 am
Bayer Ballroom

Opening Remarks

  • Chief Innovation Officer, PHS; President, Partners HealthCare International
8:00 am – 8:50 am
Bayer Ballroom

Implementing AI in Cancer Care

  • Associate Surgeon, BWH; Richard E. Wilson Professor of Surgery in the Field of Surgical Oncology, HMS
  • Chief, Breast Imaging Division, MGH; Professor of Radiology, HMS
  • President and Co-Founder, LunaDNA
  • Delta Electronics Professor, Electrical Engineering and Computer Science Department, MIT
  • Director, Cancer Genome Analysis, Broad Institute; Professor of Pathology, HMS
  • CEO, insitro
8:50 am – 9:40 am
Bayer Ballroom

Imagining Medicine in the Year 2054

In 1984 Isaac Asimov was asked to predict what life in 2019 would be like. Using the same aperture, we as what will health care look like 35 years from now? What capabilities will clinicians have that they now struggle with? And what will be the biggest challenges? Current trends suggest that we will see some significant gains in the areas of cancer immunotherapy, gene therapy for devastating rare diseases, and treatments for common neuropsychiatric conditions, including schizophrenia and depression. Panelists will draw on their visionary perspective and will reflect on what to expect and why.

Moderator: Keith Flaherty, MD
  • Director, Clinical Research, MGH; Professor of Medicine, HMS
  • Vice Chair for Scientific Innovation, Department of Medicine, BWH; Associate Professor of Medicine, HMS
  • Director, Cellular Immunotherapy Program, MGH; Assistant Professor, Medicine, HMS
  • Vice-Chair, Neurology, Director, Genetics and Aging Research Unit, MGH; Joseph P. and Rose F. Kennedy Professor of Neurology, HMS
  • CEO, Biogen
9:40 am – 10:10 am
10:10 am – 10:40 am
Bayer Ballroom
10:40 am – 11:30 am
Bayer Ballroom

CEO Roundtable

Moderator: Anne Klibanski, MD
  • Chief Academic Officer, PHS; Laurie Carrol Guthart Professor of Medicine, Academic Dean for Partners, HMS; 2019 Forum Co-Chair
  • EVP and Chief Commercial Officer, Bristol-Myers Squibb
  • CEO, Philips
  • EVP, Head, Pharmaceuticals Research & Development, Bayer AG
  • CEO, Siemens Healthineers
  • CEO, GE Healthcare
11:45 am – 1:00 pm

Discovery Cafe Sessions

Lunch with Top Leading Experts: Intensive sessions addressing cutting-edge artificial intelligence topics.

Back Office of the Provider Future

Moderator: Peter Markell, EVP, Administration and Finance, CFO and Treasurer, PHS

Kent Ivanoff, CEO, VisitPay

Connie Moser, Chief Operating Officer, Verge Health


Chief Digital Strategy Officer Roundtable

With the advent of healthcare AI-enabled technologies, this session brings together several chief digital health officers from a range of organizations. The discussion will address key tradeoffs in sequencing technology across academic medical centers; what technologies are being prioritized; and how consumer expectations are impacting the future delivery model of healthcare.

Moderator: Alistair Erskine, MD, Chief Digital Health Officer, PHS

Michael Anderes, Chief Innovation and Digital Health Officer, Froedtert Health; President, Inception Health

Adam Landman, MD, VP and CIO, Brigham Health; Associate Professor of Emergency Medicine, HMS

Aimee Quirk, CEO, innovationOchsner

Richard Zane, MD, Chief Innovation Officer, UCHealth; Professor and Chair,Department of Emergency Medicine, University of Colorado School of Medicine


Innovation Fellows: A New Model of Collaboration

The Innovation Fellows Program provides short-term, experiential career development opportunities for future leaders in health care focused on accelerating collaborative innovation between science and industry. It facilitates personnel exchanges between Harvard Medical School staff from Partners’ hospitals and participating biopharmaceutical, device, venture capital, digital health, payor and consulting firms. A successful example of open innovation, Fellows and Hosts learn from each other as they collaborate on projects ranging from clinical development to digital health & artificial intelligence to new care delivery models and industry disruption. Come listen to the experience and insights of our panelists, including Fellows, Industry Partners and hospital leadership, and learn how this new model of collaboration can deliver value and lead to broader relationships between industry and academia.


Last Mile: Fully Implementing AI in Healthcare

Moderator: Keith Dreyer, DO, PhD, Chief Data Science Officer, PHS; Vice Chairman, Radiology, MGH; Associate Professor, Radiology, HMS

Katherine Andriole, PhD, Director of Research Strategy and Operations, MGH & BWH CCDS; Associate Professor, Radiology, HMS

Samuel Aronson, Executive Director, IT, Personalized Medicine, PHS

Seth Hain, VP of R&D, Epic

Jonathan Teich, MD, PhD, Chief Medical Information Officer, InterSystems; Emergency Medicine, BWH


Reimagining Disease Management

Moderator: Sree Chaguturu, MD, Chief Population Health Officer, PHS; Assistant Professor, Medicine, HMS

Murray Brozinsky, Chief Strategy Officer, Conversa

Jean Drouin, MD, CEO, Clarify Health Solutions

Sandhya Rao, MD, Senior Medical Director, Population Health, PHS; Assistant Professor, Medicine, HMS


Standards and Regulation: The Emerging AI Framework


From Startup to Impact (Provider Solutions)

With all the hype surrounding AI, this session will focus on what really matters. Impact! Who is really moving the needle for healthcare providers today? This session will introduce you to five leading companies who will share their client stories over lunch.

Moderator: Meredith Fisher, PhD, Partner, Partners Innovation Fund, PHS


1:00 pm – 1:10 pm
1:10 pm – 2:00 pm
Bayer Ballroom

China: AI Enabled Healthcare Leadership

Moderator: James Bradner, MD
  • President, Novartis Institutes for Biomedical Research
  • CEO, Infervision
  • Managing Partner, Qiming Venture Partners
2:00 pm – 2:30 pm
Bayer Ballroom

1:1 Fireside Chat: Mark Benjamin, CEO, Nuance

Moderator: Peter Slavin, MD
  • President, MGH; Professor, Health Care Policy, HMS
  • CEO, Nuance Communications
2:30 pm – 3:00 pm
3:00 pm – 3:50 pm
Bayer Ballroom

Getting to the AI Investment Decision

  • VP, Venture & Managing Partner, Partners Innovation Fund, PHS
  • Managing Director, Bain Capital Life Sciences
  • Managing Partner, Polaris Partners
  • SVP, Strategy, Commercialization & Innovation, Amgen
  • Managing Director, Healthcare Group, Goldman Sachs
  • Partner, Google Ventures
3:50 pm – 4:20 pm
Bayer Ballroom
4:20 pm – 5:10 pm
Bayer Ballroom

Consumer Healthcare and New Models of Care Delivery

Moderator: Diana Nole
  • CEO, Wolters Kluwer Health
  • President, Global Strategy Group, Samsung; Founder, CareVisor
  • VP and Global CTO, Sales, Dell EMC
  • President, Health Platforms, Verily Life Sciences
  • VP and Chief Health Officer, IBM Corporation
  • SVP, Head of Innovation and Health Equity Microsoft Healthcare
5:15 pm – 6:15 pm

Wednesday, April 10, 2019

7:00 am – 12:00 pm
7:30 am – 9:30 am
Bayer Ballroom

Innovation Discovery Grant Awardee Presentations

Twelve clinical AI teams culled through the Innovation Discovery Grant program present their work illustrating how AI can be used to improve patient health and healthcare delivery. This session is designed for investors, entrepreneurs, investigators, and others who are interested in commercializing AI opportunities that are currently in development with support from the Innovation Office.

Moderator: David Louis, MD
  • Pathologist-in-Chief, MGH; Benjamin Castleman Professor of Pathology, HMS
9:30 am – 10:00 am
10:00 am – 10:30 am
Bayer Ballroom

1:1 Fireside Chat: Stefan Oelrich, Member of the Board of Management; President, Pharmaceutical, Bayer AG

Moderator: Betsy Nabel, MD
  • President, Brigham Health; Professor of Medicine, HMS
  • Member of the Board of Management, Bayer AG; President, Pharmaceutical, Bayer AG
10:30 am – 11:00 am
Bayer Ballroom

1:1 Fireside Chat: Deepak Chopra, MD, Founder, The Chopra Foundation

Moderator: Rudolph Tanzi, PhD
  • Vice-Chair, Neurology, Director, Genetics and Aging Research Unit, MGH; Joseph P. and Rose F. Kennedy Professor of Neurology, HMS
  • Founder, The Chopra Foundation
11:00 am – 11:50 am
Bayer Ballroom

Using AI to Predict and Monitor Human Performance and Neurological Disease

  • Chief of Neurology, Co-Director, Neurological Clinical Research Institute, MGH; Julieanne Dorn Professor of Neurology, HMS
  • Chief Scientist, Dolby Laboratories
  • Global Therapeutic Head, Neuroscience Janssen Research & Development
  • EVP and CMO, Biogen
  • CEO, Kitman Labs
11:50 am – 12:50 pm
Bayer Ballroom

Disruptive Dozen: 12 Technologies that will reinvent AI in the Next 12 Months

The culture of innovation throughout Partners HealthCare naturally fosters robust discussions about new “disruptive” technologies and which ones will have the biggest impact on health care. The Disruptive Dozen was created to identify and rank the technologies that Partners faculty feel will break through over the next decade to significantly improve health care. This year, the Disruptive Dozen focuses on relevant advances and opportunities in artificial intelligence (AI).

Moderator: Jeffrey Golden, MD
  • Chair, Department of Pathology, BWH; Ramzi S. Cotran Professor of Pathology, HMS
  • Associate Chief, Infection Control Unit, MGH; Assistant Professor, Medicine, HMS
1:00 pm – 1:10 pm
Bayer Ballroom

Read Full Post »

Artificial intelligence can be a useful tool to predict Alzheimer

Reporter: Irina Robu, PhD

The Alzheimer’s Association estimate that around 5.7 million people live with Alzheimer’s disease in the United States which will rise to almost 14 million by 2050. Earlier diagnosis would not only benefit those affected, but it could also jointly save about $7.9 trillion in medical care and related costs over time. As Alzheimer’s disease progresses, it changes how brain cells use glucose. This alteration in glucose metabolism shows up in a type of PET imaging that tracks the uptake of a radioactive form of glucose called 18F-fluorodeoxyglucose. By giving instructions about what to look for, the scientists were able to train the deep learning algorithm to assess the PET images for early signs of Alzheimer’s.
The researchers from University of California San Francisco used positron-emission tomography images of 1002 people’s brain to train the deep learning algorithm they developed. They used 90 percent of images to teach the algorithm to spot features of Alzheimer’s disease and the remaining 10 percent to verify its performance. The researchers tested the algorithm on PET images of brains from 40 people, from which they were able to predict which individuals would receive a final diagnosis of Alzheimer’s. On average, the people who were tested were diagnosed with the disease more than 6 years after the scans.
According to the Radiology journal in which the research was published, the team describes how the algorithm “achieved 82 percent specificity at 100 percent sensitivity, an average of 75.8 months prior to the final diagnosis.” The researchers taught the algorithm with the help of more than 2,109 PET images of 1,002 individuals’ brains. The algorithm uses deep learning, which allows the algorithm to “teach itself” what to look for by spotting subtle differences among the thousands of images. The algorithm was as good as, if not better than, human experts at analyzing the FDG PET images.
Future advances will involve using larger data sets and additional images taken over time from people at various clinics and institutions. In the future, the algorithm could be a beneficial addition to the radiologist’s toolbox and advance opportunities for the early treatment of Alzheimer’s disease.



Read Full Post »

Artificial Intelligence in Health Care and in Medicine: Diagnosis & Therapeutics

Reporter: Aviva Lev-Ari, PhD, RN


News You Need to Know Today

Monday, January 21, 2019

Top Stories

Mayo Clinic researchers use AI, EKG test to detect heart condition

AI applied to an electrocardiogram (EKG) test reliably detected asymptomatic left ventricular dysfunction (ALVD)—a precursor to heart failure—and predicted which patients were most at risk of developing the condition in the future, according to a Mayo Clinic study.

Radiologists at Belgian hospital adopt Aidoc neuro tool into workflows

The radiology department at the Antwerp University Hospital in Belgium has incorporated an Aidoc tool that uses AI to help radiologists make faster diagnoses from CT scans, the university announced Wednesday, Jan. 16.

AI algorithm outperforms doctors at finding cervical cancer

AI may be better at spotting cervical cancer and precancer after a study found a deep-learning algorithm was more accurate at recognizing the disease than human doctors.

Machine learning detects, treats UTIs earlier

Scientists at the University of Surrey in Guildford, England, developed a tool that uses machine learning to identify and treat urinary tract infections at early stages in dementia patients, according to a study published in PLOS One.

Featured Articles

GE Healthcare, Vanderbilt to develop AI-powered apps for immunotherapy cancer treatments

GE Healthcare and the Vanderbilt University Medical Center (VUMC) have partnered to develop diagnostic tools and AI-powered applications to create safer and more precise immunotherapy treatments for cancer patients.

AI-powered app can screen for anemia with fingernail picture

An Atlanta research team has developed a smartphone app that can screen for anemia just by taking a picture of a person’s fingernails—paving the way for a new, noninvasive method to detect and diagnose the condition.


[Video Presentation] Architecting AI: Rethinking Medical Imaging & Defining the Strategy

Jan 30, 2019 | 2PM ET We asked the questions you want to: Why is imaging ripe for AI? How will improvements in image processing and reconstruction, quality control and work list prioritization improve the practice of radiology? Register today.


From: AI in Healthcare <>

Reply-To: AI in Healthcare <>

Date: Monday, January 21, 2019 at 7:30 AM

To: Aviva Lev-Ari <>

Subject: Diagnostics | January 2019

Read Full Post »

McKinsey Top Ten Articles on Artificial Intelligence: 2018’s most popular articles – An executive’s guide to AI

Reporter: Aviva Lev-Ari, PhD, RN


The year’s most popular articles on artificial intelligence

An executive’s guide to AI

1. An executive’s guide to AI
Staying ahead in the accelerating artificial-intelligence race requires executives to make nimble, informed decisions about where and how to employ AI in their business. One way to prepare to act quickly: know the AI essentials presented in this guide. More →

Notes from the AI frontier: Applications and value of deep learning

2. Notes from the AI frontier: Applications and value of deep learning
An analysis of more than 400 use cases across 19 industries and nine business functions highlights the broad use and significant economic potential of advanced AI techniques. More →

What AI can and can’t do (yet) for your business

3. What AI can and can’t do (yet) for your business
Artificial intelligence is a moving target. Here’s how to take better aim. More →

4. The economics of artificial intelligence
Rotman School of Management professor Ajay Agrawal explains how AI changes the cost of prediction and what this means for business. More →

5. Notes from the AI frontier: Modeling the impact of AI on the world economy
Artificial intelligence has large potential to contribute to global economic activity. But widening gaps among countries, companies, and workers will need to be managed to maximize the benefits. More →

6. The executive’s AI playbook
It’s time to break out of pilot purgatory and more effectively apply artificial intelligence and advanced analytics throughout your organization. Our interactive playbook can help. More →

7. Artificial intelligence: Why a digital base is critical
Early AI adopters are starting to shift industry profit pools. Companies need strong digital capabilities to compete. More →

8. The promise and challenge of the age of artificial intelligence
AI promises considerable economic benefits, even as it disrupts the world of work. These three priorities will help achieve good outcomes. More →

9. The real-world potential and limitations of artificial intelligence
Artificial intelligence has the potential to create trillions of dollars of value across the economy—if business leaders work to understand what AI can and cannot do. More →

10. How artificial intelligence and data add value to businesses
Artificial intelligence will transform many companies and create completely new types of businesses. The cofounder of Coursera, AI Fund, and Landing.AI shares how businesses can benefit. More →


From: McKinsey Top Ten <>

Reply-To:” <>

Date: Thursday, January 3, 2019 at 3:03 PM

To: Aviva Lev-Ari <>

Subject: Artificial Intelligence: 2018’s most popular articles

Read Full Post »

Older Posts »